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Abstract
This paper comments on the role and emergence of the biopsychosocial model in modern medical
literature and health care settings. The evolution of the biopsychosocial model and its close
association with modern pain theory is also examined. This paper seeks to discuss the place of this
model with respect to the management of hypothyroidism. This discussion represents a forerunner
to a randomised control trial that will seek to investigate the effect of a biopsychosocial-based
treatment regime on hypothyroidism.
Method
A search through Medline, Meditext, PubMed, OVID, Sci-
ence direct, Austats, CINAHL, Expanded Academic ASAP
was performed using the key words: Biopsychosocial
model, hypothyroidism, treatment, levothyroxine,
thyroid.
What is the Biopsychosocial model?
The biopsychosocial model depicts a health care concept
that has evolved in close association with current pain the-
ory. It has sought coexistence with the dominant biomed-
ical model of health care, which describes 'disease' as a
failure of or within the soma, resulting from infection,
injury or inheritance [1]. The biomedical model has its
roots in the Cartesian division between mind and body
[2].
In 1977, Engel described a crisis that modern medicine
and psychiatry were facing. Disease, from a biomedical
perspective was described in somatic parameters alone,
there was little or no room for psychological, social and
behavioural dimensions of illness within this model. This
made adherence to this framework very difficult. There
were somatic and mental disorders that simply did not fit
the biomedical model, and hence it was no longer suffi-
cient for the scientific and social responsibilities of either
medicine or psychiatry [2,3]. Engel set out to develop a
new framework that would account for the biological,
psychological and social dimensions of illness and dis-
ease. It was essential that this new model provide a basis
for the understanding and treatment of disease, whilst tak-
ing into account the patient, his/her social context and the
impact of illness on that individual from a societal per-
spective [4,5]. This represented the development of the
biopsychosocial model [2].
The biopsychosocial model states that ill health and dis-
ease are the result of an interaction between biological,
psychological and social factors. The biopsychosocial
model makes the distinction between pathophysiological
processes that cause disease and the client's perception of
their health and the effects on it, called the illness [6]. It
seeks to build upon the biomedical model. Biological
indices are still held in high regard, however, they repre-
sent only one of the defining factors for the diagnosis and
management of disease under a biopsychosocial frame-
work [2]. The biopsychosocial model describes psycho-
logical and social effects of disease risk, prevention,
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treatment compliance, morbidity, quality of life and sur-
vival [4].
Situations paradoxically arise in medicine in which a per-
son who feels well is described biochemically, as having
'disease'. In contrast, a client's laboratory findings may
reveal no 'disease', however the client still feels unwell.
The biopsychosocial model provides a conceptual frame-
work for dealing with such situations [2].
Of late, a great deal of attention has been given to the fac-
tors involved in chronic pain and depression. It is research
like this that has highlighted the need for a paradigm such
as the biopsychosocial model in the management of con-
ditions other than chronic pain. Following the success of
various psychological and cognitive interventions in the
reduction of somatic signs and symptoms associated with
certain conditions such as irritable bowel syndrome (IBS),
non-cardiac chest pain, fibromyalgia and rheumatoid
arthritis (RA), research has set out to explore the role of
psychosocial factors in the disease process [3,7,8].
The biopsychosocial model avoids a strong 'disease' focus
and seeks to address the client and his or her illness [9].
Clients are helped not only with biological disruptions,
but also with their capacity to deal with being ill. It is pro-
posed that this approach may be of benefit in reducing the
frequency of clinic visits, hospitalisations, laboratory
investigations and use of pharmacological agents.
Changes in ones ability to cope, inherent belief systems as
well as behavioural and social processes associated with
being ill may also be improved through the implementa-
tion of this model [10].
The Evolution of the Biopsychosocial Model
The biopsychosocial model represents the evolution of
the biomedical model, and aligns favourably with recent
ideas in pain theory and pathophysiology [3].
Early theories concerning pain were consistent with the
specificity theory, which described pain as the result of
noxious stimuli or somatic pathology alone [11]. There
was little or no place for the influence of psychological or
social factors within these original theories [3].
The mid nineteen sixties saw the emergence of the gate
control theory of pain [11,12]. The theory proposed by
Melzack and Wall, represented a more concise model that
took into account the multidimensional nature of pain,
allowing for physiological factors and the role of the brain
in the processing of nociceptive stimuli. The gate control
theory depicts three dimensions of pain, a sensory-physi-
ologic, motivational-affective and a cognitive evaluative
dimension. Scope for the influence of environmental fac-
tors on pain also exists within the body of this theory. The
gate control model also provides a basis for understand-
ing the depression and cognitive and motivational shifts
witnessed in chronic pain situations [3,11].
Melzack through his study of phantom limb pain (pain
that is localised in the region of a deafferented body part,
subsequent to the loss of a limb)[13] developed the neu-
romatrix model [3,14] of pain. This model builds upon
the gate control model and represents one of the more
recent ideas in pain theory. The neuromatrix theory pro-
poses that the various dimensions of pain experience are
the result of a neural network program called the neuro-
matrix. This neuromatrix is influenced by genetic factors
in conjunction with cognitive, sensory and affective expe-
riences, which are individual specific. This model states
that the unified pain experience depicts an aggregate of
information from somatosensory, limbic and thalamo-
cortical pathways.
The end product is the cyclic processing of neural infor-
mation into a characteristic pattern, known as the neu-
rosignature. Melzack postulates that a neurosignature
exists for all types of pain, mood and psychological states
[3,14]. The neuromatrix is also described as having both
static and dynamic qualities, meaning that the neurosig-
nature can be influenced/modified through learning and
experience [14-17].
Put into context, this model suggests that neurosignatures
for pain and depression exist throughout the neuromatrix.
These signatures cannot be erased, but can be altered if
changes are made to the entire network [3,11,14].
The biopsychosocial model has emerged over the past two
decades and has sought to expand upon disease para-
digms and complement pain models. It states that in
order to understand and manage ill health, pain and dis-
ease, one must take into account the influence of biologi-
cal, psychological and social factors [7].
Biological Factors
It is acknowledged that there are many conditions (eg
osteoarthritis and rheumatoid arthritis)[3] in which the
symptoms experienced by clients are strongly linked to
peripheral factors such as, inflammation or cartilage dam-
age. These represent examples of biological disruption
under a biopsychosocial framework. Previously, the influ-
ence of psychological and social factors on these condi-
tions was considered of little importance and treatment
was directed to areas of somatic pathology or nociceptive
input [3]. Historically, the underlying disease process
could account for many if not all of the biological features
of disease and ill health. In this instance a biomedical
treatment strategy could be implemented with high effi-
cacy. It is important to note that the biomedical modelChiropractic & Osteopathy 2005, 13:5 http://www.chiroandosteo.com/content/13/1/5
Page 3 of 9
(page number not for citation purposes)
has not been replaced. There are a number of diseases that
can be diagnosed and managed without any considera-
tion of psychosocial factors (eg. legionnaires disease and
toxic shock syndrome) [18].
In contrast, the existence of pain and discomfort in condi-
tions such as fibromyalgia, irritable bowel syndrome
(IBS) and noncardiac chest pain is strongly linked to cen-
tral nervous system (CNS) disturbance (eg. altered central
processing) and psychosocial factors [3,7,8]. From a
biopsychosocial perspective, biological factors represent
one determinant of ill health and disease. Biological dis-
ruption may exhibit inconsistent weighting amongst vari-
ous conditions, but it represents an essential component
of diagnosis and management under the biopsychosocial
model [2].
Psychological Factors
Research into chronic pain and depression has revealed a
number of significant psychological factors [19]. Clients
experiencing pain lasting for prolonged periods of time
often display a series of maladaptive coping responses
that can influence the pain experience [3,10]. These
responses include catastrophizing, perceived low self-effi-
cacy and perceived helplessness. Clients presenting with
the above responses, often report higher pain levels than
those subjects that do not display these responses
[3,19,20].
Psychological intervention (eg pain-coping strategies, cog-
nitive behavioural therapy {CBT}) aimed at these mala-
daptive patterns and behaviours has demonstrated high
rates of success in reducing symptomatology and disease
progression in certain chronic pain conditions [3,10,20].
One area pain researchers are currently exploring is the
differences in information processing and recall bias
between chronic pain sufferers who present with comor-
bid depression and those non-depressed pain groups. It
appears that clients with chronic pain demonstrate a pro-
pensity for recalling the negative information regarding
their condition, in the presence of co-morbid depression.
Clients without depression demonstrate a recall bias for
positive illness related information. These studies suggest
that depressed patients with chronic pain may be process-
ing information differently to the non-depressed groups
[3].
Pincus and Morley propose a model to account for the
bias in information processing (specifically cognitive
bias) demonstrated in chronic pain sufferers [21]. It is
postulated that bias is the result of intersection of three
schemas representing pain, illness and self. Within these
schemas is a store of information that can interact and
influence the processing of information. The pain schema
encompass sensory intensity, along with spatial and tem-
poral features of pain. The schema accounts for the imme-
diate properties of the pain experience. They depict the
interruption of ongoing behaviour and the commence-
ment of pain avoidance and recuperative behaviours.
The illness schema depict information relating to affective
and behavioural consequences of illness (eg. goal attain-
ment, both long and short term and quality of life etc.).
The identity, timeframe, perceived causes and conse-
quences along with control of a particular illness, make up
the schema.
The schema representing self is described in a number of
ways. The self can be explained as 'an organized cognitive
structure within long-term memory, which may incorpo-
rate both general trait like information about the self, as
well as specific behaviours' [21]. The self can be viewed as
temporally dynamic processing and assimilating informa-
tion throughout life [21].
It is stated that contemporary individuals are striving to
meet their positive goals and avoid unwanted outcomes
[21]. This is determined by components of the self-
schema and their projections as to what they might
become. Illness, pain and other significant life events have
the potential to disrupt aspects of the self. For example
repeated pain whilst performing a specific task can inter-
fere with or result in failure to complete that task.
Variations in the state of a person may be explained by the
interaction of these schema. Activation of elements from
one particular schema has the potential to simultaneously
activate components of another schema, in a process
known as enmeshment. Consequently, the activation of
one schema via a relatively innocuous stimulus following
enmeshment, can elicit unwanted effects (eg illness
behaviour associated with pain syndromes) [21].
Recent studies performed by Buer and Linton describe the
importance of cognitions (fear-avoidance beliefs and cat-
astrophizing) in chronic pain situations [22]. The model
used by Buer and Linton describe fear-avoidance specifi-
cally, as a fear of movement /(re) injury, which predispose
to catastrophizing and avoidance, which in turn could
lead to disuse, disability and depressive symptoms [22].
Social Factors
There exists a considerable amount of data on the social
determinants of ill health and disease. One of the contrib-
utors to this body of knowledge has been the Whitehall
studies. The Whitehall I study initiated in the late 1960's,
examined mortality rates over 10 years among male Brit-
ish Civil Servants aged 20–64 [23]. The Whitehall study
sought to expand on the issue of the social class grouping,Chiropractic & Osteopathy 2005, 13:5 http://www.chiroandosteo.com/content/13/1/5
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and counter some of the problems associated with this
topic. Participants were physically examined and asked to
complete questionnaires regarding their jobs, smoking
habits in conjunction with personal and family medical
histories. Certain participants were asked about car own-
ership, physical activity at work and general leisure activ-
ity, which completed the list of socio-economic outcome
measures. The results of the study depicted an inverse
association between grade (level) of employment and
mortality from CHD and a range of other causes was
observed [23].
The Whitehall II study was set up to investigate the effect
of social gradient on morbidity and mortality, including
determinants such as, work characteristics and social sup-
port [24]. Measures taken into consideration were, grade
of employment, depressive symptoms, physical function-
ing, psychosocial work characteristics, life events and
material problems and health related behaviour. The
results revealed that some risk factors contribute jointly to
the inequalities witnessed in mental and physical health.
The incidence of secondary psychological stress associated
with physical ill health is more prevalent in lower employ-
ment grades. Work was deemed most important in ine-
qualities in depressive symptoms amongst men. Amongst
female respondents, work and material disadvantage were
equally salient in explaining inequalities in depressive
symptoms [24].
There are various social factors that have gained recogni-
tion in recent years with respect to influences on depres-
sion among pain patients. Patients who report high family
conflict and low family cohesion often display higher
depression levels. Likewise, patients with low socio-eco-
nomic status and lower levels of education also exhibit
higher depression scores. Research into this area high-
lights a number of studies in which psychological inter-
vention involving spouses or caregivers resulted in
reduced pain and psychological distress [3].
In a recent review, Truchon describes a set of socio-demo-
graphic factors that have featured in chronic disability
(related to low back pain) studies over the last decade
[25]. These include; age, sex, education, ethnic back-
ground and financial compensation. Ringel et al describes
a diagnostic protocol for irritable bowel syndrome (IBS),
encompassing social factors such as, break up of a close
relationship, early life experience, familial dysfunctions
and family environment. It is postulated that these factors
may influence the development of symptoms, clinical
expression, course of the disorder and the utilization of
health services [7].
Hypothyroidism
Hypothyroidism refers to any metabolic state that results
from a decrease in the amount of circulating thyroid hor-
mones in the body. Hypothyroidism can be classified
based on its time of onset (congenital or acquired), sever-
ity (overt {clinical} or mild {subclinical}), and the degree
of endocrine aberration (primary or secondary) [26]. Pri-
mary hypothyroidism follows a dysfunction of the thy-
roid gland itself, whereas secondary hypothyroidism
results from the dysfunction of metabolic or messenger
pathways associated with thyroid hormone production
and metabolism [27-29]. Primary hypothyroidism is char-
acterised by reduced free thyroxine (FT4) levels and ele-
vated thyroid stimulating hormone (TSH) levels.
Diagnosis of secondary hypothyroidism presents as a clin-
ical challenge as TSH levels can be reduced, normal or
slightly elevated. Evaluation of other pituitary hormones
becomes necessary in this situation [27].
According to the 1995 report from the Australian Bureau
of Statistics (ABS) 5.3/1000 males and 27.3/1000 females
experience thyroid dysfunction in Australia [30]. This fig-
ure is higher in the elderly, postmenopausal women and
various groups presenting with psychological dysfunction
[31-33]. In the United States hypothyroidism is the sec-
ond most common endocrine disorder and it has been
estimated that 18/1000 members of the general popula-
tion display decreased thyroid hormone levels [33].
Hypothyroidism and subclinical hypothyroidism are con-
sidered more common than their counterpart, hyperthy-
roidism [33,34]. Hypothyroidism is the most common
pathological hormone deficiency [26].
Aetiology
Hypothyroidism is caused by a variety of different states
and conditions. Autoimmune and iatrogenic causes con-
stitute the most common sources of reduced thyroid hor-
mone levels [26] (see table 1).
Signs and Symptoms of Hypothyroidism
Hypothyroidism manifests in a variety of different forms
[26]. Young infants and children born with deficiencies in
thyroid hormones are at risk of brain damage and mental
retardation [35,36]. Technological advancement in hor-
mone assays has revealed that hypothyroidism is a rela-
tive, rather than an absolute state [37]. In fact, a spectrum
of thyroid hormone deficiency exists. This spectrum, in
conjunction with individual differences, allows for a mul-
titude of differing hypothyroid presentations [26].
Overt hypothyroidism refers to patients with elevated thy-
roid stimulating hormone (TSH) levels and low free thy-
roxine (T4) levels. The term 'subclinical hypothyroidism'
has featured repeatedly in the literature in recent years.
Subclinical hypothyroidism is characterised by elevatedChiropractic & Osteopathy 2005, 13:5 http://www.chiroandosteo.com/content/13/1/5
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TSH concentrations associated with normal thyroxine
(T4) and triiodothyronine (T3) serum levels. Subclinical
hypothyroidism is further categorized with respect to the
following guidelines: [29,38] (see table 2).
A relatively exhaustive index of signs and symptoms is
listed below. However, it is important to keep in mind
that the manifestation of hypothyroidism is often far from
the textbook presentation. The symptoms of hypothy-
roidism can be subtle and are often confused with the
signs of aging [39,40] (see table 3).
Treatment
The current treatment of choice for individuals suffering
from hypothyroidism is supplementation using the syn-
thetic thyroid hormone, levothyroxine. Levothyroxine is
an artificial version of the naturally occurring thyroid hor-
mone, thyroxine (T4). Patients are required to take 50–
150 µg of levothyroxine daily for the rest of their lives
Table 1: Aetiology of Hypothyroidism
Category Cause
Autoimmune Hashimoto's Thyroiditis, Reidels Disease, previous Graves disease, de Quervains thyroiditis, postpartum thyroiditis, Downs 
syndrome, family history of autoimmune disease or associated disorders (vitiligo, adrenal insufficiency, diabetes mellitus type-1, 
Sjogren's, coeliac disease), Turner's syndrome, Multiple Sclerosis, primary pulmonary hypertension
Nutritional Iodine deficiency, excess intake of goitrogens, excessive iodine intake
Environmental Radiation Exposure, exposure to polybrominated and polychlorinated biphenyls and resorcinol
Iatrogenic Radioactive iodine therapy, medical radiation exposure, total or subtotal thyroidectomy, drugs impairing thyroid function 
(amiodarone, thalidomide, betaroxine, lithium carbonate, stavudine, aminoglutethimide)
Hypothalamic Hypothalamic or suprasellar mass, history of hypothalamic radiotherapy or surgery, disorders causing hypothalamic 
dysfunction (eg sarcoidosis, heamochromatosis)
Pituitary Known pituitary tumour, other elements of hypopituitarism, manifestations of sellar mass, history of pituitary surgery or 
radiotherapy, history of head trauma
Other Postpartum status
Table 2: Subclinical Hypothyroidism Grading System
Grade TSH levels Thyroxine (T4) levels
1 TSH above normal limits of reference range Normal
2 TSH; 10.1–20 mU/L Normal
3 TSH > 20 mU/L Normal
Table 3: Signs and Symptoms of Hypothyroidism
System Symptoms
Central Nervous System Depression, fatigue, lethargy, forgetfulness, decreased concentration, memory deficit, slow thinking, cold intolerance, nerve 
entrapment syndromes, decreased sweating, ataxia
Musculoskeletal Muscular weakness, cramps, myalgia, arthralgia, and delayed relaxation phase of reflexes
Cardiovascular Bradycardia, diastolic hypertension, increased serum cholesterol, raised triglycerides, raised low-density lipoproteins, ascites, 
hyperhomocysteinaemia
Gastrointestinal Constipation
EENT Puffy eyes, enlarged tongue, hearing impairment, goitre, hoarseness of voice, dysphagia, sore throat
Genito-Urinary Infertility, menstrual irregularities, heavy bleeding, impotence, galactorrhea, hyperprolactinemia
General Weight gain, dry and coarse skin, brittle hair and nails
Radiological Pericardial and pleural effusions, pituitary gland enlargementChiropractic & Osteopathy 2005, 13:5 http://www.chiroandosteo.com/content/13/1/5
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[31,34]. Thyroid hormones are monitored every 6–12
months to ensure that hormone levels are being main-
tained within physiological norms [31,32,34,41].
Hypothyroidism, Mood Disorders and Stress
Depression is one of the major symptoms associated with
hypothyroidism. According to the DSM-IV, a person pre-
senting with depression (major depressive episode) must
either have a depressed mood or interest for two or more
weeks [42]. This mood must represent a change from the
person's normal mood; social, occupational, educational,
or other important functioning must be negatively
impaired by the change in mood. To make the diagnosis
of major depressive episode a patient must exhibit a
depressed mood or interest and four or more of the fol-
lowing symptoms; sleep increase/decrease, diminished
interest in formerly compelling or pleasurable activities,
guilt, low self esteem, poor energy, poor concentration,
appetite increase/decrease, psychomotor agitation/retar-
dation and suicidal ideation [42].
While depression is strongly associated with hypothy-
roidism, the exact mechanisms are not yet known [43-45].
Haggerty states that almost 100% of patients presenting
with severe hypothyroidism, are found to have serious
concurrent depression [37]. It is well established that
patients presenting with a decreased thyroid status exhibit
higher lifetime frequency of depression than euthyroid
subjects [46]. Furthermore, patients with major depres-
sion have a poorer response to antidepressant medication
if they are hypothyroid [47,48]. Subclinical hypothy-
roidism may also reduce the threshold for the occurrence
of major depression [46,47].
Research has sought to explain the above findings via the
concept of central and peripheral hypothyroidism [46]. It
is postulated that central abnormalities in thyroid hor-
mone economy will not necessarily manifest in static
peripheral hormone assays [49]. Therefore, serum thyroid
hormone levels may appear normal in the presence of a
central deficiency.
Gunnarsson et al suggests that biological correlates may
exist for some of the depressive symptoms of hypothy-
roidism [50]. These include CSF CCK-4 (an anxiogenic
peptide) and trytophan (the precursor to serotonin), as
well as serum thyroid hormone levels [50].
It has been suggested that central serotonergic activity is
reduced in hypothyroid patients. It is also postulated that
comparatively higher thyroid stimulating hormone (TSH)
levels may be a predictor of lower serotonin mediated
endocrine responses and the presence of clinical depres-
sion [44]. Depression is associated with a deficiency in
brain serotonergic (5-HT) activity. Duval postulates that
the changes witnessed in hypothalamic pituitary thyroid
(HPT) axis hormones during major depressive episodes,
may be regarded as compensatory changes in order to cor-
rect reduced central serotonergic activity [44].
Sullivan states that transthyretin, a thyroid carrier protein,
exists in differing forms both centrally and peripherally
[46]. This carrier protein appears reduced in the cerebros-
pinal fluid (CSF) of depressed patients, which prevents
the transport of thyroid hormones to the brain [45,46,49].
Alterations in central nervous system (CNS) thyroid hor-
mone levels have a major effect on the serotonergic,
adrenergic and GABAergic systems. Sher states that the
brain utilizes thyroid hormones differently to other
organs, it appears especially sensitive to subtle thyroid
insufficiency. This means that thyroid function may sig-
nificantly affect mood, behaviour, and cognitive function
[45].
Research into stress, immunity and the HPT axis has dem-
onstrated some interesting findings. In a recent study
investigating the effects of stress on rat brains, Friedman et
al suggested that acute stress may alter the levels of thyroid
hormone T3, but not T4 in the rat brain [51]. Bauer et al
researched the effects of chronic stress on hormone secre-
tion in human subjects [52]. Thyroid hormone concentra-
tions were assessed in a group of 84 East German refugees
suffering from various psychiatric disorders. The results
demonstrated reductions in both TSH and thyroid hor-
mone concentrations. It was postulated that these results
reflect severe chronic stress as opposed to the effects of
psychiatric illness or thyroid dysfunction [52]. Cremaschi
et al analysed the effects of chronic stress on the thyroid
axis and its influence on the immune response in animals.
The results showed that the thyroid hormones could be
influenced by chronic stress, in particular T3 concentra-
tions. Furthermore it was postulated that changes in thy-
roid axis function may play a role in regulation of the
immune response [53].
Bauer et al describe a study in which a significant number
of patients with prophylaxis resistant affective disorders
(bipolar depression, unipolar depression, schizoaffective
disorder) improved after being given supra-physiological
doses of synthetic thyroid hormone [54]. It was suggested
that this method of intervention may represent a useful
and well-tolerated maintenance treatment for patients
presenting with these subcategories of mood disorders
[54].
There is a multitude of evidence highlighting the impor-
tance of the HPT axis in depression [37,49]. Alterations in
thyroid hormones witnessed in mood disorders are
unquestionable and this increased understanding of the
role of thyroid hormones has lead to improvements in theChiropractic & Osteopathy 2005, 13:5 http://www.chiroandosteo.com/content/13/1/5
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management of depression [48]. There is however, evi-
dence to dispute the relationship between thyroid dys-
function and mood disorders. The state of the literature as
a whole suggests an association between thyroid dysfunc-
tion and depressive disorder, however the mechanism is
unclear [55]. Engum et al describe a study of a large ran-
domly selected population group examining the risk of
anxiety disorders or depression in individuals with thy-
roid dysfunction. The results of this study showed a higher
prevalence of depression in groups with previously
known thyroid disorders, with lower prevalence in those
with more recently diagnosed thyroid dysfunction. This
study demonstrated a weak association between thyroid
disorder and symptoms of anxiety and depression. Based
on the results of their study Engum et al suggests that
when depression and anxiety disorders are diagnosed in
thyroid dysfunction sufferers, they should be treated as
separate entities, and considered that these common con-
ditions can occur and coexist without influencing each
other [55]. Baldini et al described similar findings in a
study of psychopathology and subclinical hypothy-
roidism. It was stated that when interfering factors related
to individual vulnerability to depression and perception
of disease were excluded, there was no direct correlation
between subclinical hypothyroidism and mood disorders
[56].
Fountoulakis et al suggests that the information available
on hypothyroidism and depression does not demonstrate
a causal relationship [57]. Stating that overt thyroid dys-
function is uncommon in depressed patients. Instead
those authors suggest the presence of an underlying
autoimmune process, which may affect thyroid function
in depressed populations [57].
The Biopsychosocial Model and Hypothyroidism
The biopsychosocial model represents a health concept. It
depicts a treatment paradigm that acknowledges the con-
tribution of biological, psychological and social factors in
the disease process [2]. Alonso states that the biopsycho-
social model is gaining acceptance within academic and
institutional contexts [1]. This change however is not nec-
essarily being reflected in the practical areas of medicine.
The biopsychosocial model has been used to obtain a bet-
ter understanding of the disease process, but its accept-
ance and incorporation into medical practice is taking
longer to transpire [1].
Hypothyroidism is a disease that has been treated rela-
tively successfully using pharmacological agents for many
years. However, the treatment and management of this
disease has been approached purely from a biomedical
standpoint. Thyroid hormone levels that are considered
inappropriate are restored using pharmacological supple-
mentation. This management requires a life long commit-
ment to drug therapy. In addition to this, significant
proportions of patients under the current management
protocol continue to experience the plethora of signs and
symptoms associated with hypothyroidism, even though
their thyroid hormone levels are returned to normal
[26,27]. In a recent review by Roberts et al it was stated
that approximately one fifth of hypothyroid patients are
receiving an inadequate thyroxine dose and a fifth are
given an excess of the synthetic thyroid hormone. Reasons
for this are postulated in table 4.
Another important issue that has been raised within the
current literature is the suitability of modern treatment
strategies for the elderly. Elderly patients often present
with an extensive list of different medications that they are
taking in combination. In prescribing an additional long-
term pharmacological agent to the patient presenting with
reduced thyroid hormone levels, practitioners must con-
sider the issue of drug interaction. This debate is especially
relevant as this group of patients makes up a substantial
proportion of the hypothyroid population [33].
It is essential that thyroid hormone levels be monitored at
prescribed intervals in those patients undergoing
levothyroxine therapy [26]. Weetman states that overzeal-
ous supplementation can lead to an increased risk of oste-
oporosis in postmenopausal women and atrial
fibrillation in the elderly [38]. Woeber states that in
patients with pre-existing angina pectoris, treatment of
hypothyroidism will result in an aggravation of symptoms
in one fifth of cases. Patients with coronary heart disease
run the risk of myocardial infarction some time after the
initiation of levothyroxine treatment [34].
Research suggests that is it important to provide multidis-
ciplinary care in chronic diseases (eg rheumatoid arthri-
tis). It is further postulated that the implementation of
programmes of this nature, may not only improve func-
tioning, but may lead to improvement in disease activity
[58]. The World Health Organisations (WHO) Interna-
Table 4: Potential causes of thyrotropin elevation in patients 
(thyroxine treated) with primary hypothyroidism
Suboptimal dosing, inadequate prescribed dosage, dispensing error
Non compliance
Progressive decrease in endogenous thyroxine production
Drug and supplement interactions
Co-morbidities
Malabsorption disorders
Autoimmune thyroiditis
Previous thyroid irradiation
Reduced thyroxine absorption
Other systemic illnessesChiropractic & Osteopathy 2005, 13:5 http://www.chiroandosteo.com/content/13/1/5
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tional Classification of Functioning, Disability and Health
(ICF), describes a framework for understanding and struc-
turing the impact of disease on individuals [59]. A per-
son's functioning and disability is described as a dynamic
interaction between health conditions and contextual,
environmental and personal factors. Health conditions
encompass disease, disorders, injuries and traumas. Con-
textual, environmental and personal factors describe the
psychosocial elements of a person's life [60]. These guide-
lines align favourably with the biopsychosocial paradigm.
It seems that while current treatment protocols for
hypothyroidism are quick and relatively cost efficient,
there is a strong influence in form, from the biomedical
model. The reductionist thinking associated with this
model may be the cause of the inherent problems associ-
ated with the current treatment. As the biopsychosocial
model gains credibility, it seems plausible that there may
be a place for this paradigm in the management of
hypothyroidism. If this disease were to be approached
from a more wholistic standpoint, solutions to current
management problems may be revealed. It is also feasible
that if this disease were approached using a different
model, factors in addition to pure biological influences
may be discovered. Research into thyroid hormones and
mood disorders further highlights the need for investiga-
tion in this area. A framework such as the biopsychosocial
model seems to be a plausible model of inquiry.
Conclusion
The biopsychosocial model represents the latest ideas in
chronic illness management and compliments recent
ideas in pain theory. It states that in order to rationalise
and contend with chronic conditions, one must take into
account the influence of biological, psychological and
social factors. The biopsychosocial model is gaining
acceptance within educational institutions and medical
fields and is proving very successful in the areas in which
it is applied [1]. Hypothyroidism is one chronic condition
that may benefit from the application of the biopsychoso-
cial model. Application of biopsychosocial-based inter-
ventions/therapies may help mediate some of the signs
and symptoms associated with hypothyroidism. If noth-
ing else this model represents an adjunctive framework
that may facilitate a more consistent management of this
chronic disease.The authors plan a randomised control
trial that will seek to investigate the effect of a biopsycho-
social-based treatment regime on hypothyroidism
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